Validation of the new Positron Emissions Tomography (PET) Radioligand (+)-[18F]-Flubatine for Imaging of Nicotinic Acetylcholine Receptors (nAChR) in Alzheimer’s Dementia

Organizational Data

DRKS-ID:
DRKS00005819
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2014-04-01
Last update in DRKS:
2023-03-30
Registration type:
Prospective

Acronym/abbreviation of the study

+Flubatine

URL of the study

No Entry

Brief summary in lay language

This clinical study has been started to improve the diagnostics of Alzheimer Dementia (AD). With our new radioligand (+)-[18F]-NCFHEB, Alzheimer Dementia imaging and evaluation will be possible for Positron Emissions Tomography (PET). The study is structured into pre-examination, ß-Amyloid-PET/MRI examination, the main studyday (PET examination with (+)-[18F]-NCFHEB) and a post-examination. 20 patients with Alzheimer Dementia and 20 subjects without Alzheimer Dementia will be included in this study. Additional 3-5 subjects will be used to determine exact radiation exposure values.

Brief summary in scientific language

This clinical study has been started to improve the diagnostics of Alzheimer Dementia (AD). With our new radioligand (+)-[18F]-NCFHEB, Alzheimer Dementia imaging and evaluation will be possible for Positron Emissions Tomography (PET). As the name implies, (+)-[18F]-NCFHEB is a radioactive substance, which binds at nicotinic acetylcholine receptors and can be depicted via PET-examination. This study will help to find differences in the transmission of this substance between healthy controls and patients with alzheimer dementia and will help in finding fitting therapy.The study is structured into pre-examination, ß-Amyloid-PET/MRI examination, the main studyday (PET examination with (+)-[18F]-NCFHEB) and a post-examination. 20 patients with AD and 20 subjects without AD (healthy controls) will be included in this study. Additional 3-5 subjects will be used to determine exact radiation exposure values.

Health condition or problem studied

ICD10:
F00 - Dementia in Alzheimer disease
Free text:
healthy volunteers
Healthy volunteers:
Yes

Interventions, Observational Groups

Arm 1:
(+)-[18F]-NCFHEB-PET for patients with Alzheimer`s Dementia
Arm 2:
(+)-[18F]-NCFHEB-PET for subjects without Alzheimer`s Dementia

Endpoints

Primary outcome:
Examination of (+)-[18F]-Flubatine as in-vivo marker of brain α4β2 nicotinic acetylcholine receptor availability in patients with mild Alzheimer’s disease compared to healthy controls and its evaluation for clinical routine. This will be evaluated on the informations gathered through the (+)-[18F]-Flubatine PET investigation.
Secondary outcome:
1. Determination of the pharmacokinetic parameters and exposure to radiation by (+)-[18F]-Flubatine 2. Determination of safety and tolerability of (+)-[18F]-Flubatine 3. Development of a kinetic model in order to quantitatively describe regional central α4β2 nAChR availability in the brain of patients with AD, as well as healthy volunteers

Study Design

Purpose:
Pharmacogenetics
Allocation:
Non-randomized controlled study
Control:
  • Active control (effective treatment of control group)
Phase:
I
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Parallel
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Monocenter study
Recruitment location(s):
  • University medical center Klinik und Poliklinik für Nuklearmedizin Leipzig
  • University medical center Klinik und Poliklinik für Psychiatrie und Psychotherapie Leipzig

Recruitment period and number of participants

Planned study start date:
2014-04-15
Actual study start date:
2014-04-11
Planned study completion date:
No Entry
Actual Study Completion Date:
2015-11-30
Target Sample Size:
40
Final Sample Size:
34

Inclusion Criteria

Sex:
All
Minimum Age:
55 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
Healthy volunteers: 1. Males/females aged older than or equal to 55 years of age, females must be without childbearing potential (confirmed by either: age ≥ 60; or history of hysterectomy; or hormone analysis in serum: Estradiol ≤ 20 pg/mL and follicle stimulating hormone (FSH) ≥ 40 IU/L, or last spontaneous bleeding at least 2 years prior to the study start) 2. Able to understand the information provided on purpose and conduct of the clinical study 3. Have signed the informed consent to participate in the study 4. No history of any psychiatric or neurological diseases. Clinical Dementia Rating (CDR) score of 0 (zero) and psychometric test results lying within an interval of one standard deviation from the mean value (mean value and standard deviations adjusted for age and education), for all subtests of the test battery applied. 5. Adequate visual and auditory abilities to complete neuropsychological testing, as assessed by the recruiting investigator 6. ≥ 1 year no smoking or passive smoking AD patients 1. Males/females aged older than or equal to 55 years of age; females must be without childbearing potential (confirmed by either: age ≥ 60; or history of hysterectomy; or hormone analysis in serum: Estradiol ≤ 20 pg/mL and follicle stimulating hormone FSH ≥ 40 IU/L, or last spontaneous bleeding at least 2 years prior to the study start) 2. Capable of understanding the information provided on purpose and conduct of the clinical study and able to give meaningful informed consent by himself / herself 3. Have signed the informed consent to participate in the study 4. Adequate visual and auditory acuity to complete neuropsychological testing, as assessed by the recruiting investigator 5. AD patients, characterized by: o Progressive cognitive decline with DSM-IV criteria for Dementia o Probable Alzheimer Disease according to the NINCDS-ADRDA criteria o Severity of dementia: mild, with a score of 1 on the Clinical Dementia Rating (CDR) and 20-26 on the Mini Mental State Examination (MMSE) 6. ≥ 1 year no smoking or passive smoking

Exclusion Criteria

All subjects: 1. Haematological or biochemical parameters that are outside the normal range and are considered clinically significant by the investigator. 2. History of alcohol or drug abuse/dependence 3. History of major allergic reactions 4. History of epilepsy 5. History of electroconvulsive therapy 6. Any significant disease or unstable medical condition (e.g. unstable angina, myocardial infarction or coronary revascularization in the preceding 12 months, cardiac failure, chronic renal failure, chronic hepatic disease, severe pulmonary disease, blood disorders, poorly controlled diabetes, chronic infection) 7. Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the volunteer’s safety 8. Participants in whom magnetic resonance imaging (MRI) is contraindicated. 9. Patient / Volunteer is in custody by order of an authority or a court of law 10. Exclusion periods from other studies or simultaneous participation in other clinical studies 11. Patient / Volunteer has received another investigational drug in the preceding 2 months 12. Previous enrollment in this study 13. Active Smokers 14. Interuption of central acting drugs less than 5 to 10 half lifes is not possible 15. Inadequate collateral circulation of the hand AD patients: 1. History, physical or imaging findings of other neurological illness apart from AD such as cerebrovascular disease, inflammatory or infectious disease and other degenerative diseases or other types of dementia such as fronto-temporal lobe dementia or Lewy body disease. Healthy volunteers: 1. Clinical significant abnormal physical examination 2. Evidence of any significant psychiatric or neurological illness from history, clinical or para – clinical findings 3. History, physical or imaging findings of any significant neurological illness such as cerebrovascular disease, inflammatory or infectious disease and other neurodegenerative diseases 4. Previous significant occupational exposure to ionizing radiation or in whom, within the last 10 years, radioactive substances or when ionizing radiation was applied for the purposes of research. (According to § 24 Abs. 1 Nr. 6 StrlSchV / § 28b Abs. 1 Nr. 6 RöV)

Addresses

Primary Sponsor

Address:
Universität Leipzig
Ritterstraße 26
04109 Leipzig
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Universitätsklinikum Leipzig, Klinik und Poliklinik für Nuklearmedizin
Martin Wehner
Liebigstraße 18
04103 Leipzig
Germany
Telephone:
03419718107
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://nuklmed.uniklinikum-leipzig.de/

Contact for Public Queries

Address:
Universitätsklinikum Leipzig, Klinik und Poliklinik für Nuklearmedizin
Martin Wehner
Liebigstraße 18
04103 Leipzig
Germany
Telephone:
03419718107
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://nuklmed.uniklinikum-leipzig.de/

Principal Investigator

Address:
Universitätsklinikum Leipzig, Klinik und Poliklinik für Nuklearmedizin
Martin Wehner
Liebigstraße 18
04103 Leipzig
Germany
Telephone:
03419718107
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://nuklmed.uniklinikum-leipzig.de/

Sources of Monetary or Material Support

Private sponsorship (foundations, study societies, etc.)

Address:
Universität Leipzig
04109 Leipzig
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Institutional budget, no external funding (budget of sponsor/PI)

Address:
Universitätsklinikum Leipzig AöR
04103 Leipzig
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Address:
Geschäftsstelle der Ethik-Kommission an der Medizinischen Fakultät der Universität Leipzig c/o Zentrale Poststelle
Liebigstraße 18
04103 Leipzig
Germany
Telephone:
+49-341-9715490
Fax:
+49-341-9715499
Contact per E-Mail:
Contact per E-Mail
URL:
http://home.uni-leipzig.de/ethik

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2012-08-30
Ethics committee number:
442/12-24092012
Vote of the Ethics Committee:
Approved
Date of the vote:
2013-10-25

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
2012-003473-26
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
(+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer’s disease and healthy controls
Date of first publication of study results:
2020-09-16
DRKS entry published for the first time with results:
2020-11-13

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry